Introduction {#s1}
============

Cartilage-hair hypoplasia (CHH, OMIM \#250250) is caused by mutations in *RMRP*, which encodes the long non-coding RNA component of mitochondrial RNA-processing endoribonuclease. CHH is characterized by metaphyseal chondrodysplasia, hair hypoplasia, combined immunodeficiency, anemia, and increased risk of malignancies. Autoimmune (AI) diseases have occasionally been reported in CHH, such as enteropathy, hemolytic anemia (AIHA), hypoparathyroidism, hypo- or hyperthyroidism, juvenile rheumatoid arthritis and neutropenia ([@B1]--[@B4]). The prevalence of asthma is increased and has been reported in 16% (4/25) of Amish and 24% (10/34) of Finnish patients ([@B3], [@B5]). Allergic rhinoconjunctivitis is also excessively prevalent (41%, 23/56) in the Finnish CHH population ([@B6]).

*RMRP* mutations induce cell cycle abnormalities resulting in defective proliferation and increased apoptosis of T cells ([@B7], [@B8]). Patients with CHH have markedly reduced numbers of recent thymic emigrants and low naïve CD4+ and CD8+ cells, but normal counts of CD4+CD25~high~CD127~low~ regulatory T cells and double-negative T cells ([@B6], [@B8]). Eosinophilia and increased immunoglobulin (Ig) E levels are uncommon ([@B6]).

The knowledge of the disease mechanisms in CHH has expanded in recent years to include impaired gene regulation ([@B9]) and defects in telomere biology ([@B10], [@B11]). In addition, lack of autoimmune regulator (AIRE) expression and absence of Foxp3+ T cells in the thymus of a single patient with CHH has been reported ([@B12]). The loss of AIRE function associated with *AIRE* mutations is responsible for Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), a recognized polyendocrine syndrome with defective T and B cell tolerance ([@B13], [@B14]). This could support a possible role of impaired regulatory T cell function in the pathogenesis of CHH.

We have recently demonstrated broad autoantibody reactivity in subjects with CHH using the microarray technique ([@B15]). Compared with healthy controls, CHH patients showed significantly higher reactivity for autoantibodies against gliadin, nuclear antigens, thyroglobulin, vitronectin, as well as for myositis-specific antibodies.

In order to further explore the prevalence and characteristics of AI and allergic manifestations in individuals with CHH, we analyzed clinical and laboratory data for a large group of Finnish CHH patients. We also tested serum samples from several of these patients for a variety of autoantibodies. To complement our previous research, we applied different measurement methods and tested mostly for autoantibodies that were not included in our recent study ([@B15]).

Methods {#s2}
=======

We originally invited all known Finnish patients with CHH to a prospective cohort study in 1985--1991. Those who agreed to participate (Cohort 1, *n* = 80) underwent interview, clinical examination and blood sampling; *RMRP* mutation testing was performed when the gene was identified in 2001. A follow-up visit was conducted in 2012--2015, when Cohort 1 and all other thus far identified Finnish CHH patients were contacted and invited for a clinical visit and blood tests. This study thus included three groups of patients (in total 104 patients): (1) patients from Cohort 1 who attended the follow-up visit (*n* = 32), (2) patients from Cohort 1 who were unavailable for the follow-up visit (*n* = 48), and (3) patients recruited to the study at the follow-up visit (Cohort 2, *n* = 24). We collected complete data by means of interviews and from hospital records for all patients participating the follow-up visit (*n* = 56). For those patients from Cohort 1 who did not attend the follow-up visit, we obtained health information from two Finnish National Medical Databases. The Care Register for Health Care has since 1969 recorded the activities of health centers, hospitals and other institutions providing inpatient care, as well as home-nursing care. Outpatient primary health care data was derived from the Register of Primary Health Care Visits, which covers all health centers in Finland since 2011. Database information included health service providers, dates of the visits, diagnoses, as well as diagnostic and therapeutic procedures. We then contacted all identified hospitals and requested all patients\' detailed health records for the analysis. Special attention was given to the signs and symptoms attributed to autoimmunity, such as skin rashes, joint symptoms and gastrointestinal complaints and they were systematically discussed during the interviews.

Asthma diagnosis was made by physicians and/or pulmonologists using spirometry and assessment of response to asthma medications. Allergy was similarly diagnosed by physicians based on clinical presentation and in some cases, on skin tests and/or serum specific IgE levels. Sepsis diagnosis was made by physicians and supported by positive findings in blood cultures.

Serum samples for autoantibody measurement were obtained from those who agreed to donate blood at the follow-up visit (*n* = 33) and stored at −70°C until analyses. The analyzed autoantibodies were related to celiac disease, based on frequent gastrointestinal complaints among the patients, and on autoantibodies that are commonly seen in patients with *AIRE* mutations (Table [1](#T1){ref-type="table"}). One of the eight chosen autoantibodies (deamidated gliadin peptide IgG) has previously been tested with microarray technique in 16 of the available 33 samples ([@B15]).

###### 

Antibody assays performed on serum samples of patients with cartilage-hair hypoplasia.

  **Antibody**                     **Abbreviation**   **Measurement method**                                **Normal values in adults[^\*^](#TN1){ref-type="table-fn"}**
  -------------------------------- ------------------ ----------------------------------------------------- --------------------------------------------------------------
  Deamidated gliadin peptide IgA   DGP-IgA            FEIA                                                  \<7 U/ml
  Deamidated gliadin peptide IgG   DGP-IgG            FEIA                                                  \<7 U/ml
  Tissue transglutaminase IgA      tTG-IgA            FEIA                                                  \<7 U/ml
  Tissue transglutaminase IgG      tTG-IgG            FEIA                                                  \<10 U/ml
  Endomysium IgA                   EMA-IgA            IIF                                                   Titer \<5
  Endomysium IgG                   EMA-IgG            IIF                                                   Titer \<5
  Interleukin 17 IgG               IL-17              Radioligand binding[^1^](#TN2){ref-type="table-fn"}   \<218 Index
  Interleukin 22 IgG               IL-22              Radioligand binding[^1^](#TN2){ref-type="table-fn"}   \<270 Index
  Interferon ω IgG                 IFN-ω              Radioligand binding[^2^](#TN3){ref-type="table-fn"}   \<200 Index
  21-Hydroxylase IgG               21-OH              Radioligand binding[^3^](#TN4){ref-type="table-fn"}   \<57 Index

*FEIA fluorometric enzyme immunoassay, Ig immunoglobulin, IIF indirect immunofluorescence*,

*Age-specific institutional reference values were used to evaluate results in pediatric patients*.

*([@B16])*.

*([@B17])*.

*([@B18])*.

To further evaluate the cause for symptoms related to rhinoconjuctivitis we examined nasal samples for eosinophilic, neutrophilic and goblet cells from five patients with physician-diagnosed allergic rhinitis. Subjects had refrained from application of local nasal decongestants, steroids or systemic antihistamines prior to sampling. Samples were taken during spring and summer months (May--August), from both anterior nares beneath the middle turbinates using a standard cotton swab. Samples were let to set on a glass slide at room temperature. Cytology was evaluated by an experienced technician using eosin-methylene blue staining and microscopy.

Statistical analyses were performed with IBM SPSS version 23 software. Fisher\'s exact test, logistic regression analysis and Kaplan-Meier method were implicated when appropriate.

The study protocol was approved by the Institutional Research Ethics Committee at Helsinki University Hospital, Finland, and informed consents were obtained from all participants and caregivers.

Results {#s3}
=======

Our study group included 104 patients (61 women, 43 men) with genetically confirmed CHH. Their median age at the last follow-up was 39.2 years (range 0.6--73.6 years). There were 17 children aged \<18.0 years, 49 young adults (18.0--45.0 years) and 38 adults aged \>45.0 years. The majority of patients (*n* = 79; 76%) were homozygous for the g.70A\>G *RMRP* mutation, others were compound heterozygous for g.70A\>G and either g.262G\>T (*n* = 22; 21%) or duplication TACTCTGTGA at −13 (*n* = 3; 3%).

Altogether 11 patients (11/104, 10.6%) had been diagnosed with AI conditions (Table [2](#T2){ref-type="table"}*)*. Clinical features of all study patients are presented in Table [3](#T3){ref-type="table"}. In addition to AI diseases that have been previously reported in patients with CHH (enteropathy, hemolytic anemia, hyperthyroidism, and juvenile rheumatoid arthritis), we report psoriasis, idiopathic thrombocytopenic purpura, narcolepsy, and multifocal motor axonal neuropathy all of which have been regarded as autoimmune diseases ([@B19]--[@B22]).

###### 

Autoimmune conditions diagnosed in 11 out of 104 patients with cartilage-hair hypoplasia.

  **No**.   **AI disease**                                    **Age at diagnosis of AI disease, yrs**   **Age at the latest follow-up, yrs**   **Treatment**                                                    **Outcome of AI disease**                                       **Other symptoms**
  --------- ------------------------------------------------- ----------------------------------------- -------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------
  1         Enteropathy                                       3                                         Died in young adulthood                None specific                                                    Died from pneumonia following bowel occlusion                   Anemia, arthralgia, asthma, pneumonia
            MMAN                                              28                                                                               IVIG                                                             Moderate clinical improvement                                   
  2         Seronegative juvenile polyarthritis               6                                         Young adulthood                        NSAIDs, i/a and oral steroids, MTX, HCQ, leflunomide             Etanercept is under consideration for relapsing arthritis       None
  3         AIHA                                              10                                        Young adulthood                        IVIG                                                             Remission after 9 yrs of treatment                              Arthralgia, Hirschsprung disease, lymphoma, pneumonia, sepsis
  4         Narcolepsy                                        11                                        Young adulthood                        None specific, narcolepsy was not related to influenza vaccine   No remission                                                    Allergy, anemia
  5         AIHA                                              11                                        Died in adolescence                    Prednisolone                                                     Remission after short course of therapy                         Anemia, pneumonia, sepsis
            Psoriasis                                         12                                                                               Local therapy                                                    Disease under control until death                               
            Enteropathy                                       14                                                                               None specific                                                    Died from pneumonia following profound diarrhea                 
  6         Graves\' disease                                  15                                        Young adulthood                        Carbimazole, thyroidectomy                                       Cured after thyroidectomy                                       Allergy, arthralgia
  7         ITP                                               29                                        Died in adulthood                      Prednisolone                                                     Remission after 1.5 yrs of therapy. Died from lymphoma          Allergy, arthralgia, diarrhea, lymphoma, pneumonia, sepsis
  8         Celiac disease[^\*^](#TN5){ref-type="table-fn"}   30                                        Died in adulthood                      Unknown                                                          Unknown. Died from pneumonia                                    Arthralgia, pneumonia
  9         Enteropathy                                       35                                        Young adulthood                        None specific                                                    Investigations ongoing                                          Anemia, arthralgia, pneumonia
  10        Psoriasis                                         41                                        Died in adulthood                      Local therapy                                                    Disease under control until death from lymphoma                 Allergy, arthralgia, Hirschsprung disease, lymphoma, pneumonia
  11        Ulcerative colitis                                68                                        Died in mature adulthood               Mesalamine                                                       Disease under control until death from end-stage lung disease   Allergy, asthma, bronchiectasis, meylodysplasia, pneumonia

*AI, autoimmune; AIHA, autoimmune hemolytic anemia; HCQ, hydroxychloroquine; i/a, intra-articular; ITP, idiopathic thrombocytopenic purpura; IVIG, intravenous immunoglobulin; MMAN, multifocal motor axonal neuropathy; MTX, methotrexate; No, patient number; NSAID, nonsteroidal anti-inflammatory drug; yrs, years*.

*data on histopathology is not available*.

###### 

Clinical and laboratory characteristics of 104 patients with cartilage-hair hypoplasia.

  ---------------------------------------------------------------------------------------------------------------------------------
  **Manifestations**                               **No. of patients (%)**   **Comments**
  ------------------------------------------------ ------------------------- ------------------------------------------------------
  Recurrent sinopulmonary and/or ear infections\   84/104 (81)\              Acute otitis media, rhinosinusitis and/or pneumonia\
  Hospitalization and/or surgery required          50/80 (63)                Tympanostomy and/or sinus surgery

  Physician-diagnosed asthma                       24/104 (23)               

  Allergy to pollen and/or animal\                 40/104 (39)\              Skin testing and/or allergen-specific serum IgE
  Positive allergy testing                         5/9 (56)                  

  Joint symptoms                                   56/104 (54)               Arthralgia or morning joint stiffness

  Arthrosis\                                       20/56 (36)\               Confirmed radiologically\
  Juvenile rheumatoid arthritis                    1/56 (2)                  Seronegative polyarthritis

  Gastrointestinal symptoms\                       32/104 (31)\              
  Prolonged and/or recurrent diarrhea\             23/32(72)\                
  Dyspepsia                                        18/32 (56)                

  Gastroscopy performed\                           18/32 (56)\               Normal results in eight (8/18, 44%) patients\
  Colonoscopy performed\                           8/32 (25)\                Normal in all except one case of ulcerative colitis\
  Chronic gastritis\                               5/18 (28)\                Diagnosed on gastroscopy\
  Duodenal villous atrophy                         3/18 (17)                 Diagnosed on gastroscopy

  Anemia\                                          32/104 (31)\              
  Red blood cell transfusion required\             13/32 (41)\               
  AIHA                                             2/32 (6)                  

  Elevated IgE[^\*^](#TN6){ref-type="table-fn"}    5/69 (7)                  

  Elevated deamidated gliadin peptide IgA          2/33 (6)                  Values of 9 and 20 (normal \< 7 U/ml)

  Elevated deamidated gliadin peptide IgG          2/33 (6)                  Values of 10 and 14 (normal \< 7 U/ml)

  Elevated interferon ω IgG                        1/33 (3)                  Value of 206 (normal \< 200 Index)

  Elevated 21-Hydroxylase IgG                      2/33 (6)                  Values of 67 and 77 (normal \< 57 Index)
  ---------------------------------------------------------------------------------------------------------------------------------

*AIHA, autoimmune hemolytic anemia; Ig, immunoglobulin; No, number*.

*According to local laboratory age-adjusted reference values*.

Among those with autoimmunity, recurrent pneumonia, and sepsis were more frequently documented than in those without autoimmunity (6/11, 55% vs. 13/93, 14%, *p* = 0.001, B coefficient 2.65 and 4/11, 36% vs. 6/93, 6%, *p* = 0.019, B coefficient 2.14, respectively). Rates of autoimmunity were higher in patients with elevated IgE levels (2/5, 40%; *p* = 0.011, B coefficient 2.96) and in patients with undetectable IgA levels (3/5, 60%; *p* = 0.036, B coefficient 3.33), as compared with patients with normal IgE and IgA levels.

Among patients from Cohort 1, 10/80 individuals have developed AI diseases during follow-up. The Kaplan-Meier analysis (log rank test) of these 80 patients demonstrated that survival distributions for patients with and without AI conditions were significantly different, $\chi_{(2)}^{2}$ = 14.056, *p* = 0.0002 (Figure [1](#F1){ref-type="fig"}).

![Survival of patients with cartilage-hair hypoplasia differs significantly in subjects with and without autoimmune conditions, log rank $\chi_{(2)}^{2}$ = 14.056, *p* = 0.0002.](fimmu-09-02468-g0001){#F1}

More than half of our patients (56/104, 54%) suffered from arthralgia or morning joint stiffness, but only one was diagnosed with genuine seronegative juvenile polyarthritis. Osteoarthritis was common among patients with arthralgia (20/56, 36%) and was increasingly prevalent with increasing age. Mean age at last follow-up in those with osteoarthritis was 51.7 years, while it was 35.2 years in those without osteoarthritis. Patients with a history of arthralgia reported more often sinusitis (38/56, 68% vs. 18/48, 38%, *p* = 0.002, B coefficient 1.3) and pollen allergy (27/56, 48% vs. 13/48, 27%, *p* = 0.035, B coefficient 0.95). When arthralgia, asthma and diarrhea were compiled in a Venn diagram (*n* = 71), asthma and diarrhea overlapped with arthralgia in 7 and 12 patients, respectively (Figure [2](#F2){ref-type="fig"}). The overlap, however, did not reach statistical significance. This group of 71 patients contained most of the patients with AI conditions (10/11).

![Modified Venn diagram of arthralgia, asthma, persistent diarrhea and their combinations in 71 patients with cartilage-hair hypoplasia. *n*, number of patients. Stars indicate patients with autoimmune diseases.](fimmu-09-02468-g0002){#F2}

Gastrointestinal symptoms were common in our cohort (32/104, 31%) and the most frequent complaint was prolonged/recurrent diarrhea. In at least three patients with diarrhea, broad screening for bacterial, viral and parasitic infections was negative. Twelve patients followed lactose-free diet, but this did not alleviate diarrhea. Eight patients had undergone colonoscopy, with normal results in all except one subject with ulcerative colitis. Gastroscopy findings were abnormal in 10/18 patients and included gastroesophageal reflux (*n* = 5), chronic gastritis (*n* = 5), peptic ulcer (*n* = 2), and/or duodenal villous atrophy (DVA, *n* = 3). Another patient had received the diagnosis of celiac disease, but data on histology were unavailable. Significantly more patients with diarrhea reported arthralgia (18/23, 78% vs. 38/81, 47%, *p* = 0.011, B coefficient 1.41), as compared with those without diarrhea. In the subgroup of patients with osteoarthritis (*n* = 20), diarrhea was not more common than in those without osteoarthritis.

Anemia was diagnosed in 32 patients (31%), mostly in childhood. Thirteen of these patients (41%) required red blood cell transfusions. Two subjects had AIHA, in others anemia was hypoplastic and attributed to CHH itself and mostly resolved by adulthood. Four of the patients required blood transfusions as adults. There were no cases of AI neutropenia, but one patient had idiopathic thrombocytopenic purpura.

Physician-diagnosed asthma (23%) and allergy (39%) were both highly prevalent. Asthma was diagnosed in 29% (5/17) of children and in 22% (19/87) of adults. In some patients with clinical symptoms of pollen allergy, skin testing and/or serum allergen-specific IgE testing had been negative. Elevated IgE levels were infrequently documented (5/69 patients), also in subjects without allergic symptoms. Eosinophilia was more common in subjects with pollen allergy (5/34, 15% vs. 1/50, 2%, *p* = 0.038). Hospitalization for pneumonia and/or surgery for sinopulmonary and/or ear infections were more common in patients with asthma \[19/24 (79%) vs. 31/80 (39%), *p* = 0.019, B coefficient 1.13\].

Subgroup of patients tested for autoantibodies
----------------------------------------------

Serum samples were available from 33 adult patients (21 women, 12 men) at median age of 45.4 years (range 19.9--69.1 years). One patient was receiving immunoglobulin substitution at the time of blood sampling, he tested negative for all autoantibodies. One had unmeasurable IgA, therefore EMA-IgG and tTG-IgG were measured in serum with normal results. In a few patients, we detected slightly elevated autoantibodies including anti-interferon-ω IgG (IFN-ω, *n* = 1), anti-21-hydroxylase IgG (21-OH, *n* = 2), anti-gliadin-peptide IgA (*n* = 2) and anti-gliadin-peptide IgG (*n* = 2; Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). These patients had no celiac disease and none of the typical manifestations of APECED, including adrenal insufficiency, hypoparathyroidism and mucocutaneous candidiasis. All other autoantibodies tested negative in all patients.

###### 

Results of autoantibody measurements in 33 patients with cartilage-hair hypoplasia.

  **Pt No**.   **AI**   **Arthralgia**   **G/i**   **Pollen allergy**   **BA**   **DGP-IgA, U/ml**   **DGP-IgG, U/ml**   **tTG-IgA, U/ml**                      **EMA-IgA, titer**                     **IL-17, index**   **IL-22, index**   **IFN-ω, index**   **21-OH, index**
  ------------ -------- ---------------- --------- -------------------- -------- ------------------- ------------------- -------------------------------------- -------------------------------------- ------------------ ------------------ ------------------ ------------------
  1            --       \+               --        \+                   \+       \<7                 \<7                 \<7                                    \<5                                    211                −52                34                 23
  2            --       --               --        --                   --       \<7                 **14**              \<7                                    \<5                                    −5                 81                 64                 55
  3            --       \+               --        \+                   --       **20**              **10**              7                                      \<5                                    −2                 −9                 62                 −27
  4            --       \+               --        \+                   --       \<7                 \<7                 \<7                                    \<5                                    64                 2                  −50                −34
  5            --       --               --        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −49                −25                0                  6
  6            --       \+               \+        --                   --       7                   7                   \<7                                    \<5                                    −37                30                 13                 40
  7            --       \+               \+        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −30                −70                111                11
  8            --       \+               \+        \+                   --       \<7                 \<7                 \<7                                    \<5                                    31                 101                155                35
  9            --       \+               \+        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −28                −7                 49                 −33
  10           --       \+               \+        \+                   \+       \<7                 \<7                 \<7                                    \<5                                    −53                84                 49                 47
  11           --       \+               \+        --                   --       \<7                 \<7                 \<7                                    \<5                                    −62                23                 −39                −21
  12           --       --               \+        \+                   \+       \<7                 \<7                 \<7                                    \<5                                    −40                90                 136                **67**
  13           --       \+               --        \+                   \+       \<7                 \<7                 \<7                                    \<5                                    −84                −95                −48                −30
  14           --       \+               --        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −27                99                 22                 15
  15           --       --               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    −10                −60                171                46
  16           --       --               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    −32                39                 29                 11
  17           --       \+               --        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −32                73                 48                 77
  18           --       --               \+        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −62                −11                −46                7
  19           --       \+               --        \+                   \+       \<7                 \<7                 \<7                                    \<5                                    −52                −110               −110               −4
  20           --       \+               \+        --                   --       **9**               \<7                 \<7                                    \<5                                    −42                −27                −86                −21
  21           --       --               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    −26                15                 −36                46
  22           --       \+               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    16                 105                130                **77**
  23           --       --               \+        --                   --       \<7                 \<7                 \<7                                    \<5                                    −59                50                 79                 54
  24           --       --               --        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −66                3                  54                 16
  25           --       --               --        --                   --       \<7                 \<7                 \<7[^\*^](#TN7){ref-type="table-fn"}   \<5[^\*^](#TN7){ref-type="table-fn"}   51                 37                 68                 18
  26           --       \+               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    −38                −10                42                 21
  27           --       --               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    48                 183                −194               −4
  28           --       --               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    −98                −71                −71                −1
  29           --       \+               \+        --                   --       \<7                 \<7                 \<7                                    \<5                                    −69                −18                −45                4
  30           --       --               \+        \+                   \+       \<7                 \<7                 \<7                                    \<5                                    −69                19                 −202               −30
  31           --       --               --        --                   --       \<7                 \<7                 \<7                                    \<5                                    −8                 66                 **206**            38
  32           --       --               \+        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −32                90                 69                 30
  33           --       \+               \+        \+                   --       \<7                 \<7                 \<7                                    \<5                                    −51                −17                40                 40

*Numbers in bold represent elevated values. For reference values please see Table [1](#T1){ref-type="table"}*.

*Because of immunoglobulin A deficiency diagnosed in this patient, tTG-IgG and EMA-IgG were measured, both were negative. 21-OH, 21-hydroxylase; AI, autoimmune disease; BA, bronchial asthma; DGP, deamidated gliadin peptide; EMA, endomysium; G/i, gastrointestinal symptoms; IFN, interferon; Ig, immunoglobulin; IL, interleukin; No, number; Pt, patient; tTG, tissue transglutaminase*.

Subgroup of patients tested for nasal cytology
----------------------------------------------

Nasal samples were available from five patients. Although they all reported physician-diagnosed allergic rhinitis, eosinophils were almost absent in all subjects, only two out of five subjects had single cells visible unilaterally (Table [5](#T5){ref-type="table"}). Further, neutrophils were detected in moderate amounts in only one patient, and goblet cells in another. Lymphocytes were not found in any samples.

###### 

Cytology of nasal cells from five subjects with cartilage-hair hypoplasia.

                 **Subject 1**   **Subject 2**   **Subject 3**   **Subject 4**   **Subject 5**                                 
  -------------- --------------- --------------- --------------- --------------- --------------- ------ ------- ------ ------- ------
  Nasal side     Right           Left            Right           Left            Right           Left   Right   Left   Right   Left
  Lymphocytes    --              --              --              --              --              --     --      --     --      --
  Eosinophils    --              (+)             --              --              --              --     (+)     --     --      --
  Neutrophils    --              \+              --              \+              --              --     (+)     (+)    ++      ++
  Goblet cells   ++              ++              (+)             (+)             --              --     --      --     (+)     (+)

*Grading of eosinophilic cells (per microscopic view): --, 0 cells; +/-, 1-3 cells; +, 3--5 cells; ++, 20--30 cells; +++, cells predominate. Grading of neutrophilic cells (per microscopic view): --, no cells; +, cells clearly visible; ++, moderate number of cells visible*.

Discussion {#s4}
==========

We demonstrate high prevalence (11/104, 10.6%) of AI conditions in a large cohort of Finnish patients with CHH compared with the prevalence of 5.4% in general Finnish population ([@B23]). Autoimmunity, allergy, diarrhea, arthralgia, and asthma in our patients may reflect common pathways of immune dysregulation behind these symptoms.

With microarray technique, multiple autoantibodies have been demonstrated in all (*n* = 16) tested serum samples from patients with CHH ([@B15]). The absence of compatible symptoms may reflect the benign nature of these antibodies, consistent with reported presence of autoantibodies in healthy individuals ([@B24]). *RMRP* mutations may contribute to AI phenomena by various mechanisms, such as impaired T~h~17 cell functions or altered expression of *AIRE*. Autoantibodies typically observed in APECED patients (IFN-ω, IL-17, IL-22, 21-OH) have not been included in our previous study. Here, we describe positivity for these antibodies in three of our patients, but the indices were close to the limit of positivity and the patients had no compatible clinical manifestations. Thus, the significance of these findings is uncertain.

The data on the CD4+CD25^high^CD127^low^ regulatory T cells measured in 11 patients from our cohort has previously been published ([@B6]). The numbers of regulatory T cells were normal in 10/11 patients, including two patients with autoimmunity (measured after the development of AIHA and juvenile idiopathic arthritis) and low in a single 67-year-old patient without AI manifestations. However, functional abnormalities in regulatory T cells cannot be excluded and the role of CTLA-4 deficiency behind the immune dysregulation should be further explored.

Many of our study patients described gastrointestinal problems, most commonly recurrent and/or prolonged diarrhea. Eleven of our patients avoided lactose, which did not improve diarrhea. Endoscopy was not systematically performed in patients with CHH and thus AI enteropathy cannot be excluded. The presence of DVA in three subjects with negative celiac screen underscores the necessity for systematic endoscopic evaluation of CHH individuals with gastrointestinal complaints. Apart from celiac disease, DVA is frequent in patients with common variable immunodeficiency and numerous other disorders, and DVA etiology should always be identified and treated to prevent malnutrition and malignant transformation ([@B25], [@B26]).

Serum tissue transglutaminase (tTG) IgA was negative in all tested patients and tTG IgG was negative in a single patient with IgA deficiency. However, in our previous microarray study ([@B15]), five out of 16 patients tested positive for tTG IgG and two of them reported diarrhea, therefore the possible link between tTG antibodies and gastrointestinal symptoms in patients with CHH deserves further studies. Isolated positive tTG IgG is uncommon in celiac disease, but can be present in other AI conditions, including inflammatory bowel disease ([@B27]). The discordance of positivity for tTG IgG in our current and previous study may be explained by higher sensitivity of microarray technique.

Asthma was more common in individuals with CHH who required hospitalization and/or surgery for sinopulmonary and/or ear infections. This may suggest asthma as a marker for a more severe immunodeficiency in CHH but may also reflect the retrospective nature of our study and the influence of age, with accumulation of infectious episodes and asthma diagnoses in older patients. Asthma was not associated with pollen allergy in this cohort, raising the question of possible misdiagnosis of one or both of these disorders in some patients. Asthma diagnosis is challenging in CHH due to the absence of height-age-adjusted reference values for spirometry.

Autoimmunity has been implied as a mechanism for lung disease in some patients with APECED and asthma-like symptoms, airway hyperresponsiveness and bronchiectasis ([@B28], [@B29]). We have previously demonstrated high prevalence of bronchiectasis in individuals with CHH, also in those without clinical signs of immunodeficiency ([@B5]). Thus, some patients with CHH designated to have asthma, may instead suffer from an underlying autoimmune lung disease and pulmonary problems in subjects with CHH require further investigations.

Four of the eleven patients with AI diseases died of pneumonia or end-stage lung disease. Although in three of them lung manifestations preceded the onset of autoimmunity, we suggest that patients with CHH and AI conditions should be carefully evaluated for pulmonary symptoms and consideration given for prophylactic antibiotics and/or immunoglobulin substitutions to prevent lung damage from recurrent infections.

In allergic rhinitis and asthma, eosinophils are recruited by pro-inflammatory cytokines and mediators and are the predominant cells in later phases of an allergic response ([@B30], [@B31]). The role of neutrophils in allergic inflammation is debated, but some studies report increasing numbers in nasal cytology in patients with allergic rhinitis ([@B32]--[@B34]). While all five tested subjects reported recurrent or chronic symptoms of allergic rhinitis and nasal samples were collected during the peak pollen season, none had increased numbers of eosinophilic, neutrophilic or lymphocytic nasal cells. This points to the presence of a chronic mucous inflammation, congruent with the systemic immune dysregulation, also supported by the fact that some patients with symptoms of pollen allergy tested negative for allergens.

In conclusion, we report here a high prevalence and a wide spectrum of AI diseases in a large cohort of patients with CHH. We report mild positivity for some autoantibodies, not associated with clinical autoimmunity. The high prevalence of arthralgia, persistent diarrhea, asthma and symptoms of inflammation of nasal mucosa may indicate common pathways of immune dysregulation. Gastrointestinal, pulmonary and joint symptoms in subjects with CHH should be thoroughly evaluated to exclude underlying autoimmunity.
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AI

:   autoimmune

AIHA

:   autoimmune hemolytic anemia

APECED

:   Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy

CHH

:   cartilage-hair hypoplasia

DVA

:   duodenal villous atrophy

Ig

:   immunoglobulin

IL

:   interleukin

RMRP

:   RNA component of mitochondrial RNA-processing endoribonuclease.
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